Genprex Inc
Company Profile
Business description
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex’s oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company’s lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
Contact
3300 Bee Cave Road
Suite 650-227
AustinTX78746
USAT: +1 877 774-4679
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
25
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,506.80 | 41.80 | 0.49% |
CAC 40 | 7,393.76 | 13.02 | 0.18% |
DAX 40 | 20,024.66 | 115.52 | 0.58% |
Dow JONES (US) | 42,392.27 | 151.95 | -0.36% |
FTSE 100 | 8,260.09 | 87.07 | 1.07% |
HKSE | 19,811.75 | 188.43 | 0.96% |
NASDAQ | 19,280.79 | 30.00 | -0.16% |
Nikkei 225 | 39,894.54 | 386.62 | -0.96% |
NZX 50 Index | 13,038.86 | 71.88 | -0.55% |
S&P 500 | 5,868.55 | 13.08 | -0.22% |
S&P/ASX 200 | 8,243.30 | 42.10 | 0.51% |
SSE Composite Index | 3,257.52 | 5.04 | -0.15% |